Bright Minds Biosciences (DRUG) Share-based Compensation (2020 - 2026)
Bright Minds Biosciences (DRUG) posted Share-based Compensation of $878672.4 for Q1 2026, down 4.66% on a QoQ basis from $921592.8 in Q4 2025, and up 104.71% year-over-year from $429236.4 in Q1 2025.
Bright Minds Biosciences (DRUG) Share-based Compensation (2020 - 2026) Analysis & Trends
Bright Minds Biosciences' Share-based Compensation history runs 7 years deep, the most recent figure standing at $878672.4 for Q1 2026.
- Quarterly Share-based Compensation rose 104.71% year-over-year to $878672.4 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 million (up 318.28% YoY) and the FY2025 annual result came in at $2.3 million, up 275.68% from the prior year.
- Share-based Compensation was $878672.4 for Q1 2026 at Bright Minds Biosciences, down from $921592.8 in the prior quarter.
- Across five years, Share-based Compensation topped out at $953650.7 in Q2 2025 and bottomed at $22158.3 in Q1 2023.
- A 5-year average of $355347.0 and a median of $229607.1 in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 92.33% — and 2023, when it jumped 1202.44%.
- Bright Minds Biosciences' Share-based Compensation stood at $356669.6 in 2022, then tumbled by 54.91% to $160825.8 in 2023, then declined by 21.49% to $126269.3 in 2024, then jumped by 629.86% to $921592.8 in 2025, then fell by 4.66% to $878672.4 in 2026.
- Business Quant data shows DRUG's Share-based Compensation at $878672.4 in Q1 2026, $921592.8 in Q4 2025, and $776796.1 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Bright Minds Biosciences | 498.53 Mn | 498.53 Mn | - | 878,672.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 878,672.44 |
| Mar 31, 2026 | 878,672.44 |
| Dec 31, 2025 | 921,592.84 |
| Dec 31, 2025 | 921,592.84 |
| Sep 30, 2025 | 776,796.07 |
| Sep 30, 2025 | 776,796.07 |
| Jun 30, 2025 | 953,650.69 |
| Jun 30, 2025 | 953,650.69 |
| Mar 31, 2025 | 429,236.43 |
| Mar 31, 2025 | 429,236.43 |
| Dec 31, 2024 | 126,269.35 |
| Dec 31, 2024 | 126,269.35 |
| Sep 30, 2024 | 154,116.42 |
| Sep 30, 2024 | 154,116.42 |
| Jun 30, 2024 | 134,486.72 |
| Jun 30, 2024 | 134,486.72 |
| Mar 31, 2024 | 168,194.02 |
| Mar 31, 2024 | 168,194.02 |
| Dec 31, 2023 | 160,825.82 |
| Dec 31, 2023 | 160,825.82 |